Remetinostat

Drug Overview

Remetinostat (also known as SHP-141) is a specialized cancer medication designed to treat specific types of skin-related cancers. It is a “Smart Drug” classified as a Targeted Therapy. Unlike traditional chemotherapy that travels through the entire bloodstream, remetinostat is unique because it is designed to work exactly where it is applied—on the skin—and then break down quickly so it does not cause side effects in the rest of the body.

In the corporate medical field, this is known as a “soft” drug. For patients and healthcare providers, this means the medication provides a high-standard treatment for skin lesions while protecting the health of internal organs like the liver and kidneys. It is currently a primary focus in international clinical trials for patients with early-stage skin lymphoma.

• Generic Name: Remetinostat
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Histone Deacetylase (HDAC) Inhibitor
• Route of Administration: Topical (Gel applied to the skin)
• FDA Approval Status: Investigational (Currently in Phase II/III Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how remetinostat works, imagine the DNA inside a cancer cell is a long instruction manual that has been tightly rolled up and “locked.” For the cell to stay healthy and stop growing uncontrollably, it needs to read certain “stop” signals in that manual. In skin cancer cells, these signals are often hidden.

At the molecular level, remetinostat acts as a precision key:

1. Targeting HDAC Enzymes: The drug identifies and blocks enzymes called Histone Deacetylases (HDACs). These enzymes are like “compactors” that keep DNA tightly wound around proteins called histones.
2. Acetylation Balance: By blocking these enzymes, remetinostat increases “acetylation.” This process causes the tightly wound DNA to relax and open up.
3. Gene Activation: Once the DNA is open, the cancer cell can finally read the “instructions” it was missing. Specifically, it turns on genes like p21, which tell the cell to stop dividing.
4. Cell Death (Apoptosis): When the cancer cell’s growth is frozen, it triggers a natural self-destruct sequence called apoptosis.
5. Soft-Drug Design: Once the remetinostat molecules leave the skin and enter the blood, they are immediately neutralized by enzymes in the body. This prevents the drug from “locking” DNA in healthy internal organs.

FDA-Approved Clinical Indications

As an investigational agent, remetinostat is currently used in strictly monitored clinical research settings. It is not yet approved for general sale at pharmacies.

Oncological Uses (Investigational)

• Cutaneous T-Cell Lymphoma (CTCL): Specifically for the Mycosis Fungoides subtype.
• Basal Cell Carcinoma (BCC): Investigated as a localized treatment for specific skin tumors.
• Squamous Cell Carcinoma: Early research for localized skin lesions.

Non-Oncological Uses

• There are currently no non-oncological uses for remetinostat.

Dosage and Administration Protocols

Remetinostat is prepared as a clear gel. Because it is an investigational drug, the exact strength and frequency are determined by the specific clinical trial protocol.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because the drug is designed to break down before it reaches the liver or kidneys in significant amounts, dose adjustments are typically not required for patients with mild to moderate organ impairment. However, researchers monitor these patients closely.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has shown that remetinostat is highly effective at reducing the size of skin tumors and stopping intense itching.

• Objective Response Rate (ORR): In Phase II trials for Mycosis Fungoides, approximately 40% to 56% of patients saw their skin lesions shrink significantly.
• Itch Reduction (Pruritus): Numerical data shows that over 80% of patients reported a major decrease in skin itching, which greatly improved their quality of life.
• Tumor Size: In trials for Basal Cell Carcinoma (2021-2024), researchers observed a decrease in the diameter of treated tumors in nearly 70% of participants.

Safety Profile and Side Effects

Black Box Warning:

None. (Remetinostat has a very low risk of severe systemic side effects due to its “soft drug” design).

Common Side Effects (>10%)

• Skin Irritation: Redness, stinging, or peeling where the gel is applied.
• Dry Skin: Flaking or itchiness at the application site.
• Contact Dermatitis: A mild rash where the gel touches the skin.

Serious Adverse Events

• Skin Infection: If the skin breaks down too much, bacteria may enter.
• Allergic Reaction: Rare instances of hives or swelling.
• Systemic Absorption: Although rare, very high doses over large areas could potentially affect blood counts.

Management Strategies

• Localized Care: If redness occurs, doctors may suggest skipping a dose or using a gentle moisturizer after the gel has dried.
• Monitoring: Patients undergo regular skin exams to ensure the lesions are healing and not becoming infected.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, remetinostat is being studied for its ability to “unmask” skin cancer. Scientists are exploring if remetinostat can be combined with Checkpoint Inhibitors to help the immune system recognize skin tumors more easily. There is also early-stage research into whether this drug can help healthy skin cells regenerate more effectively once the cancerous cells are cleared away.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Skin Biopsy: To confirm the exact type of skin cancer.
• Baseline Photography: To track the size and color of lesions before starting.
• Routine Blood Work: To check baseline liver and kidney function.

Precautions During Treatment

• Sun Exposure: Protect treated areas from direct sunlight, as the skin may be more sensitive.
• Application Hygiene: Wash hands before and after applying the gel. Do not apply to open or bleeding wounds.

“Do’s and Don’ts” List

• Do apply the gel at the same time every day to maintain a steady effect.
• Do report any sudden, severe skin peeling to your oncology nurse.
• Don’t cover the treated area with airtight bandages unless told to by your doctor.
• Don’t use other medicated creams on the same area without asking your research team.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Remetinostat is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or dermatologist to discuss your specific diagnosis, treatment options, and potential risks. This content reflects clinical data available as of 2026.